KRAS and neoplasm: In addition, dual targeting of miR-21 (anti-miR-21) and KRAS (siKRAS or mimic-217) packaged into the tumor-penetrating NPs decreased tumor growth in in vivo models generated from PANC-1 and D8-175 PDAC cell lines [153].